{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:21:13Z","timestamp":1787170873698,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"crossref","award":["2016YFC0104805"],"award-info":[{"award-number":["2016YFC0104805"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chinese Academy of Medical Science Initiative for Innovative Medicine","award":["2017-I2M-2-003"],"award-info":[{"award-number":["2017-I2M-2-003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12282-020-01196-8","type":"journal-article","created":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T02:03:14Z","timestamp":1609552994000},"page":"630-643","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis"],"prefix":"10.1007","volume":"28","author":[{"given":"Juan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2220-3007","authenticated-orcid":false,"given":"Zhaolian","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,2]]},"reference":[{"issue":"14","key":"1196_CR1","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.2217\/fon.14.110","volume":"10","author":"CH Yip","year":"2014","unstructured":"Yip CH, Rhodes A. Estrogen and progesterone receptors in breast cancer. Future Oncol. 2014;10(14):2293\u2013301.","journal-title":"Future Oncol"},{"issue":"5","key":"1196_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11864-018-0541-1","volume":"19","author":"I van Hellemond","year":"2018","unstructured":"van Hellemond I, Geurts S, Tjan-Heijnen V. Current status of extended adjuvant endocrine therapy in early stage breast cancer. Curr Treat Options Oncol. 2018;19(5):26.","journal-title":"Curr Treat Options Oncol"},{"issue":"23","key":"1196_CR3","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","volume":"28","author":"HJ Burstein","year":"2010","unstructured":"Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28(23):3784\u201396.","journal-title":"J Clin Oncol"},{"issue":"10001","key":"1196_CR4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"The Early Breast Cancer Trialists' Collaborative Group","year":"2015","unstructured":"The Early Breast Cancer Trialists\u2019 Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341\u201352.","journal-title":"Lancet"},{"issue":"2","key":"1196_CR5","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1158\/1078-0432.CCR-12-2153","volume":"19","author":"MP Goetz","year":"2013","unstructured":"Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res. 2013;19(2):500\u20137.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1196_CR6","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135\u201341.","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"1196_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10549-007-9700-y","volume":"105","author":"D Koeberle","year":"2007","unstructured":"Koeberle D, Thuerlimann B. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1\u201398. Breast Cancer Res Treat. 2007;105(Suppl 1):55\u201366.","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 7","key":"1196_CR8","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdl941","volume":"17","author":"F Boccardo","year":"2006","unstructured":"Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, Mesiti M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol. 2006;17(Suppl 7):i10\u20134.","journal-title":"Ann Oncol"},{"issue":"16","key":"1196_CR9","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1158\/1078-0432.CCR-05-0354","volume":"11","author":"BS Mann","year":"2005","unstructured":"Mann BS, Johnson JR, Kelly R, Sridhara R, Williams G, Pazdur R. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Clin Cancer Res. 2005;11(16):5671\u20137.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1196_CR10","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/jnci\/dji250","volume":"97","author":"PE Goss","year":"2005","unstructured":"Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262\u201371.","journal-title":"J Natl Cancer Inst"},{"key":"1196_CR11","unstructured":"Mastro LD, Mansutti M, Bisagni G, Ponzone R, Durando A, Amaducci L. Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM). In: edito, ACSO 2019 2019."},{"issue":"1","key":"1196_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(18)30621-1","volume":"20","author":"EP Mamounas","year":"2019","unstructured":"Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CJ, Rastogi P, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology\/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(1):88\u201399.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1196_CR13","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1200\/JCO.2007.14.0228","volume":"26","author":"EP Mamounas","year":"2008","unstructured":"Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol. 2008;26(12):1965\u201371.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1196_CR14","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S1470-2045(17)30600-9","volume":"18","author":"V Tjan-Heijnen","year":"2017","unstructured":"Tjan-Heijnen V, van Hellemond I, Peer P, Swinkels A, Smorenburg CH, van der Sangen M, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol. 2017;18(11):1502\u201311.","journal-title":"Lancet Oncol"},{"key":"1196_CR15","doi-asserted-by":"crossref","unstructured":"Gnant M, Steger G, Greil R, Fitzal F, Mlineritsch B, Manfreda D, et al. A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy\u2014results from 3484 postmenopausal women in the ABCSG-16 trial. In: edito, 2017 San Antonio Breast Cancer Symposium 2017.","DOI":"10.1158\/1538-7445.SABCS17-GS3-01"},{"issue":"1","key":"1196_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/jnci\/djx134","volume":"110","author":"EJ Blok","year":"2018","unstructured":"Blok EJ, Kroep JR, Meershoek-Klein KE, Duijm-de CM, Putter H, van den Bosch J, et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL Trial (BOOG 2006\u201305). J Natl Cancer Inst. 2018;110(1):40\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"1196_CR17","unstructured":"Ohtani S, Iijima K, Higaki K, Sato Y, Hozumi Y, Hasegawa Y, et al. A prospective randomized multi-center open-label phase III trial of extending aromatase-inhibitor adjuvant therapy to 10 years\u2014results from 1697 postmenopausal women in the N-SAS BC 05 trial: Arimidex extended adjuvant randomized study (AERAS). In: edito, 2018 San Antonio Breast Cancer Symposium 2019."},{"issue":"2","key":"1196_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10549-019-05464-w","volume":"179","author":"X Qian","year":"2020","unstructured":"Qian X, Li Z, Ruan G, Tu C, Ding W. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials. Breast Cancer Res Treat. 2020;179(2):275\u201385.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1196_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.afos.2018.08.002","volume":"4","author":"M Tanaka","year":"2018","unstructured":"Tanaka M, Itoh S, Takeuchi Y. Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation. Osteoporos Sarcopenia. 2018;4(3):102\u20138.","journal-title":"Osteoporos Sarcopenia"},{"issue":"3","key":"1196_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ramb.2012.12.008","volume":"59","author":"S Wiwanitkit","year":"2013","unstructured":"Wiwanitkit S, Wiwanitkit V. Postmenopausal osteoporosis, breast cancer, and aromatase inhibitor. Rev Assoc Med Bras. 2013;59(3):217.","journal-title":"Rev Assoc Med Bras"},{"issue":"1","key":"1196_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1470-2045(17)30715-5","volume":"19","author":"M Colleoni","year":"2018","unstructured":"Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(1):127\u201338.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1196_CR22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/annonc\/mdw055","volume":"27","author":"N Zdenkowski","year":"2016","unstructured":"Zdenkowski N, Forbes JF, Boyle FM, Kannourakis G, Gill PG, Bayliss E, et al. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. Ann Oncol. 2016;27(5):806\u201312.","journal-title":"Ann Oncol"},{"issue":"3","key":"1196_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1604700","volume":"375","author":"PE Goss","year":"2016","unstructured":"Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375(3):209\u201319.","journal-title":"N Engl J Med"},{"issue":"24","key":"1196_CR24","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/jnci\/djm246","volume":"99","author":"R Jakesz","year":"2007","unstructured":"Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99(24):1845\u201353.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1196_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.18.00440","volume":"37","author":"T Ruhstaller","year":"2019","unstructured":"Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, et al. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1\u201398 Trial. J Clin Oncol. 2019;37(2):105\u201314.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1196_CR26","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41571-018-0145-5","volume":"16","author":"J Richman","year":"2019","unstructured":"Richman J, Dowsett M. Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. Nat Rev Clin Oncol. 2019;16(5):296\u2013311.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1196_CR27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.21037\/gs.2018.08.03","volume":"7","author":"Z Clement","year":"2018","unstructured":"Clement Z, Kollias J, Bingham J, Whitfield R, Bochner M. Extended duration of adjuvant aromatase inhibitor in breast cancer: a meta-analysis of randomized controlled trials. Gland Surg. 2018;7(5):449\u201357.","journal-title":"Gland Surg"},{"issue":"1","key":"1196_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10549-016-3725-z","volume":"156","author":"M Martin","year":"2016","unstructured":"Martin M, Brase JC, Ruiz A, Prat A, Kronenwett R, Calvo L, et al. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM\/9906 sub-study. Breast Cancer Res Treat. 2016;156(1):81\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"1196_CR29","doi-asserted-by":"publisher","first-page":"6783","DOI":"10.7314\/APJCP.2015.16.15.6783","volume":"16","author":"MF Yazdi","year":"2015","unstructured":"Yazdi MF, Rafieian S, Gholi-Nataj M, Sheikhha MH, Nazari T, Neamatzadeh H. CYP2D6 genotype and risk of recurrence in tamoxifen treated breast cancer patients. Asian Pac J Cancer Prev. 2015;16(15):6783\u20137.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"9","key":"1196_CR30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1200\/JCO.18.01412","volume":"37","author":"M Dowsett","year":"2019","unstructured":"Dowsett M, Turner N. Estimating risk of recurrence for early breast cancer: integrating clinical and genomic risk. J Clin Oncol. 2019;37(9):689\u201392.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1196_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10549-019-05518-z","volume":"180","author":"S Yao","year":"2020","unstructured":"Yao S, Laurent CA, Roh JM, Lo J, Tang L, Hahn T, et al. Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study. Breast Cancer Res Treat. 2020;180(1):187\u201395.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1196_CR32","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1530\/JOE-19-0077","volume":"241","author":"SK Ramchand","year":"2019","unstructured":"Ramchand SK, Cheung YM, Yeo B, Grossmann M. The effects of adjuvant endocrine therapy on bone health in women with breast cancer. J Endocrinol. 2019;241(3):R111\u201324.","journal-title":"J Endocrinol"},{"issue":"3","key":"1196_CR33","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/cen.13735","volume":"89","author":"M Grossmann","year":"2018","unstructured":"Grossmann M, Ramchand SK, Milat F, Vincent A, Lim E, Kotowicz MA, et al. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone and Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia. Clin Endocrinol (Oxf). 2018;89(3):280\u201396.","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-020-01196-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-020-01196-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-020-01196-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T23:35:41Z","timestamp":1619307341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-020-01196-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,2]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1196"],"URL":"https:\/\/doi.org\/10.1007\/s12282-020-01196-8","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,2]]},"assertion":[{"value":"28 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a meta-analysis, and no study was conducted on individual participants. Therefore, neither ethical approval nor informed consent is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}}]}}